⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21561701 | 1.00 | — | — | |
| SCHEMBL24221995 | 0.85 | — | — | |
| SCHEMBL21533368 | 0.81 | LGALS8 (0.32) | — | |
| SCHEMBL19940051 | 0.79 | — | — | |
| SCHEMBL13447823 | 0.78 | LGALS8 (0.35) | — | |
| SCHEMBL12292298 | 0.77 | LGALS8 (0.33) | — | |
| SCHEMBL19631498 | 0.76 | LGALS8 (0.33) | — | |
| SCHEMBL14987856 | 0.76 | — | — | |
| SCHEMBL18390208 | 0.73 | LGALS8 (0.30) | — | |
| SCHEMBL16729887 | 0.73 | LGALS8 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739332-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-08-29 | — | — | US | disclosed |
| US-20220025376-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2022-01-27 | — | — | US | disclosed |
| US-11118215-B2 | Method for obtaining structural information concerning an encoded molecule and method for selecting compounds | NUEVOLUTION A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| US-11001835-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2021-05-11 | — | — | US | disclosed |
| US-10443058-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-10-15 | — | — | US | disclosed |
| US-10385342-B2 | Methods of treatment using antisense oligomers and conjugates targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-08-20 | — | — | US | disclosed |
| US-20190136227-A1 | METHOD FOR THE SYNTHESIS OF A BIFUNCTIONAL COMPLEX | NUEVOLUTION AS (DK) | 2019-05-09 | — | — | US | disclosed |
| US-20180216116-A1 | ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2018-08-02 | — | — | US | disclosed |
| US-20180112217-A1 | Stereospecific Phosphorothioate LNA | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2018-04-26 | — | — | US | disclosed |
| US-9879265-B2 | Oligonucleotide conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2018-01-30 | — | — | US | disclosed |
| US-20170335323-A1 | Chiral Library Screen | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2017-11-23 | — | — | US | disclosed |
| US-9725723-B2 | Compositions and methods for modulation of FGFR3 expression | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-08-08 | — | — | US | disclosed |
| WO-2011009697-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | SANTARIS PHARMA A/S (DK) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010076248-A1 | USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES | SANTARIS PHARMA A/S (DK) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010000656-A1 | RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1) | SANTARIS PHARMA A/S (DK) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009127680-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI PCSK9 OLIGOMERS | SANTARIS PHARMA A/S (DK) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009043759-A2 | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HIF1ALPHA | SANTARIS PHARMA A/S (DK) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009027527-A2 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF FABP4/AP2 | SANTARIS PHARMA A/S (DK) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008131807-A2 | SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE | SANTARIS PHARMA A/S (DK) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008043753-A2 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PCSK9 | SANTARIS PHARMA A/S (DK) | 2008-04-17 | — | — | WO | disclosed |